# Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome

> **NCT04977986** · PHASE3 · COMPLETED · sponsor: **Zynerba Pharmaceuticals, Inc.** · enrollment: 215 (actual)

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DRUG:** ZYN002 - transdermal gel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04977986
- **Lead sponsor:** Zynerba Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-13
- **Primary completion:** 2025-08-29
- **Final completion:** 2025-08-29
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04977986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04977986, "Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04977986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*